CAPA – Page 408 – Pharma.Tips

Tablet capping observed during high-speed runs – CAPA failure identified

Understanding and Investigating Tablet Capping During High-Speed Runs Tablet capping, a common manufacturing defect observed during high-speed runs, poses challenges to operational efficiency and product quality. The phenomenon can lead…

Tablet lamination defect during high-speed runs – root cause analysis breakdown

Root Cause Analysis of Tablet Lamination Defects During High-Speed Production Tablet lamination defects can pose significant challenges in pharmaceutical manufacturing, particularly during high-speed runs. This article offers a detailed investigation…

Tablet lamination defect during high-speed runs – CAPA failure identified

Identifying and Addressing Tablet Lamination Defects During High-Speed Production Runs In the fast-paced world of pharmaceutical manufacturing, particularly during high-speed tablet production, defects such as lamination can lead to significant…

Weight variation failure during stability pull – process vs formulation assessment

Addressing Weight Variation Failures During Stability Assessments: A Comprehensive Investigation Approach Weight variation failures during stability pulls pose significant challenges in pharmaceutical manufacturing, impacting product quality and regulatory compliance. This…

Friability failure during compression – root cause analysis breakdown

Analyzing Friability Failures During Compression in Tablet Manufacturing In the realm of pharmaceutical manufacturing, friability failures during the compression of tablets can be a significant concern. Such failures not only…

Weight variation failure during campaign changeover – process vs formulation assessment

Assessing Weight Variation Failures During Campaign Changeover: A Practical Approach In the realm of pharmaceutical manufacturing, weight variation failures during campaign changeover are a critical concern that can lead to…

Friability failure during campaign changeover – CAPA failure identified

Investigation of Friability Failures During Campaign Changeover in Tablet Manufacturing In the realm of pharmaceutical manufacturing, ensuring product quality during a campaign changeover is paramount. However, a friability failure can…

Disintegration time failure after tooling change – process vs formulation assessment

Addressing Disintegration Time Failures Following Tooling Changes in Tablet Manufacturing In the world of pharmaceutical manufacturing, consistent product quality is critical. When faced with disintegration time failures following tooling changes,…

Hardness drift after scale-up – FDA inspection observation risk

Addressing Hardness Drift After Scale-Up: An Investigation Approach to FDA Inspection Risks Hardness drift after scale-up is a critical manufacturing defect that can lead to Out of Specification (OOS) results…

Tablet chipping complaint after scale-up – root cause analysis breakdown

Root Cause Analysis of Tablet Chipping Complaints Following Scale-Up During pharmaceutical manufacturing, scaling up production can sometimes lead to unexpected complications, such as increased instances of tablet chipping. This can…

Tablet lamination defect after tooling change – root cause analysis breakdown

Analyzing Tablet Lamination Defects Following Tooling Changes In pharmaceutical manufacturing, discrepancies can significantly impact quality control (QC) and overall product efficacy. One common concern is a tablet lamination defect observed…

Tablet lamination defect during campaign changeover – process vs formulation assessment

Addressing Tablet Lamination Defects During Changeover: A Comprehensive Investigation Guide In the high-stakes environment of pharmaceutical manufacturing, defects such as tablet lamination can pose significant challenges, especially during campaign changeovers.…